

# CNS SPECTRUMS®

THE INTERNATIONAL JOURNAL OF NEUROPSYCHIATRIC MEDICINE

## **ORIGINAL RESEARCH**

### **Early Onset Obsessive-Compulsive Disorder With and Without Tics**

M.A. de Mathis, J.B. Diniz, R.G. Shavitt, A.R. Torres, Y.A. Ferrão,  
V. Fossaluza, C. Pereira, E.C. Miguel, M.C. do Rosario

### **Gender Differences in the Association Between Body Mass Index and Psychopathology**

R.A. Desai, M. Manley, M.M. Desai, M.N. Potenza

## **CASE REPORTS**

### **Nail-Biting Stuff?**

### **The Effect of N-acetyl Cysteine on Nail-Biting**

M. Berk, S. Jeavons, O.M. Dean, S. Dodd, K. Moss, C.S. Gama, G.S. Malhi

### **A Case of Alcohol Withdrawal Requiring 1,600 mg of Lorazepam in 24 Hours**

D.R. Kahn, A.V. Barnhorst, J.A. Bourgeois

## **PEARLS IN CLINICAL NEUROSCIENCE**

### **Borderline Personality Disorder: Toward Integration**

D.J. Stein

## **LETTER TO THE EDITOR**

### **Varenicline-induced Mixed Mood and Psychotic Episode in a Patient with Schizoaffective Disorder**

COMING SOON

intuniv<sup>TM</sup>

(guanfacine) Extended  
Release  
Tablets

## MISSION STATEMENT

*CNS Spectrums'* editorial mission is to address relevant neuropsychiatric topics, including the prevalence of comorbid diseases among patients, and original research and reports that emphasize the profound diagnostic and physiologic connections made within the neurologic and psychiatric fields. The journal's goal is to serve as a resource to psychiatrists and neurologists seeking to understand and treat disturbances of cognition, emotion, and behavior as a direct consequence of central nervous system disease, illness, or trauma.

## GENERAL

*CNS Spectrums* (ISSN 1092-8529) is published monthly by MBL Communications, Inc., 333 Hudson Street, 7th Floor, New York, NY 10013. Periodicals postage paid at New York, NY, and additional mailing offices. POSTMASTER: Send address changes to *CNS Spectrums*, 333 Hudson St., 7th Floor, New York, NY 10013.

*CNS Spectrums* is a monthly *Index Medicus*/MEDLINE journal designed to bridge the clinical information needs of 50,000 psychiatrists and neurologists. Introduced in 1996, *CNS Spectrums* reaches more physicians than any other indexed, peer-reviewed neuropsychiatric journal in the world.

In addition, the 2007 ISI Journal Citation Reports' Impact Factor for *CNS Spectrums* is 2.222. The Impact Factor is based on a total of 1,179 citations.

## EDITORIAL

*CNS Spectrums* Phone: 212-328-0800 Editor:  
333 Hudson St., 7th Floor Andrew A. Nierenberg, MD  
New York, NY 10013 Fax: 212-328-0600 Harvard Medical School  
e-Mail: [lla@mblicommunications.com](mailto:lla@mblicommunications.com)

**MANUSCRIPT SUBMISSION:** *CNS Spectrums* will consider and encourages the following types of articles for publication: **Original Research** presents methodologically sound original data; **Reviews** are comprehensive articles summarizing and synthesizing the literature on various neuropsychiatric topics and presented in a scholarly and clinically relevant fashion; and **Case Reports**, single or multiple, are encouraged for publication. Manuscripts should be submitted electronically at [www.cnsspectrums.com/asp/authorguidelines.aspx](http://www.cnsspectrums.com/asp/authorguidelines.aspx)

**PEER REVIEW:** Articles appearing in *CNS Spectrums* are peer reviewed by two independent reviewers using ScholarOne's Manuscript Central peer review program. This innovative, web-based, database-driven platform allows for easy administrative, editing, submission, and reviewing capabilities.

**LETTERS TO THE EDITOR:** Letters to the Editor should be submitted electronically at [www.cnsspectrums.com/asp/Letters.aspx](http://www.cnsspectrums.com/asp/Letters.aspx)

**INSTRUCTIONS FOR AUTHORS:** Guidelines are available at [www.cnsspectrums.com/asp/authorguidelines.aspx](http://www.cnsspectrums.com/asp/authorguidelines.aspx)

## INDEXING

*CNS Spectrums* is indexed in the Index Medicus database, EMBASE, and is available on MEDLINE under the citation *CNS Spectr.*

## SUBSCRIPTIONS AND BACK ISSUES

## ANNUAL SUBSCRIPTION RATES

	United States	International
Individuals	\$120	\$165 (US)

Institutional Pricing: Please contact [cdn@mblicommunications.com](mailto:cdn@mblicommunications.com)  
For subscriptions: Tel: 212-328-0800; Fax: 212-328-0600; Web: [www.cnsspectrums.com](http://www.cnsspectrums.com).

**SINGLE COPIES AND BACK ISSUES:** To order a single copy or a back issue, please visit <https://secure.mblcommunications.com/CNSSpec/asp/BackIssues.aspx>. Issues are \$15 per copy (including all domestic shipping costs).

**ADDRESS CHANGES:** In order to change your address, please visit [www.cnsspectrums.com/asp/ChangeOfAddress.aspx](http://www.cnsspectrums.com/asp/ChangeOfAddress.aspx). Address changes take 4-6 weeks to verify. You can also fax a letter to 212-328-0600 or mail a letter to:

*CNS Spectrums*  
Attn: Subscriptions  
333 Hudson St., 7th Floor  
New York, NY 10013

**ATTENTION AMA MEMBERS:** To change your address, you must do so through the AMA since they are the source of our subscription database. We cannot process the change for you. *Please call the AMA at 800-262-3211.*

## COPYRIGHT/FINANCIAL DISCLOSURE

**COPYRIGHT:** Materials are accepted for exclusive publication in *CNS Spectrums* and become the property of *CNS Spectrums*. Permission to reproduce material must be obtained from the publisher.

**DISCLOSURE OF COMMERCIAL AND NON-COMMERCIAL INTERESTS:** Authors must include a statement about all forms of support, including grant and pharmaceutical support, affiliations, and honoraria received for past and present material. Such information may, at the editor's discretion, be shared with reviewers. If the article is accepted for publication, all relevant disclosure information is listed.

## PERMISSIONS REQUESTS

## REQUESTS FOR PERMISSIONS MAY BE SUBMITTED VIA THE FOLLOWING METHODS:

- If you would like to electronically obtain permission to use materials (tables, figures, etc.) presented in *CNS Spectrums*, please visit <http://www.copyright.com> and enter "CNS Spectrums". You may also e-mail [cdn@mblicommunications.com](mailto:cdn@mblicommunications.com)
- If you would like to submit a written permission request, please fax or mail to the following number and/or address:

Fax: 212-328-0600  
Mail: *CNS Spectrums*  
ATTN: Permissions  
333 Hudson St., 7th Floor  
New York, NY 10013

- Permission will not be granted until the article in which the material appears has been published in *CNS Spectrums*.
- In order to complete the request, we will need the following information: Article Title, Author(s); Journal Citation (Year; Volume; Issue Number; Page Range), the Copyrighted Item to be Used, and Description of Intended Use/Audience. Please include your Name, Company, Address, Phone/Fax Numbers, and E-mail Address.
- If the permission request is approved, the journal should be cited as "CNS Spectr" followed by the article's numerical citation.
- Use of the full text of material published in *CNS Spectrums* is not permitted on other Web sites.

## EMBARGO

All materials published in *CNS Spectrums* are embargoed until the 15th of the month of publication.

## REPRINTS

For bulk reprint purchases, please contact Christopher Naccari at [cdn@mblicommunications.com](mailto:cdn@mblicommunications.com) or go to [www.cnsspectrums.com/asp/Reprints.aspx](http://www.cnsspectrums.com/asp/Reprints.aspx). Please include: Article Title; Author(s); Journal Citation; Year; Volume; Issue Number; and Quantity.

## ADVERTISING

## CONTACTS:

- **Print Ads:** Christopher Naccari, [cdn@mblicommunications.com](mailto:cdn@mblicommunications.com)
- **Classifieds:** Kimberly Schneider, [ks@mblicommunications.com](mailto:ks@mblicommunications.com)
- **Web Ads:** Robert Kadar, [rob@goodhealthadvertising.com](mailto:rob@goodhealthadvertising.com)

**MEDIA KITS:** Media Kits are available upon request in print or PDF formats. Please e-mail Kimberly Schneider, [ks@mblicommunications.com](mailto:ks@mblicommunications.com).

## DISCLAIMER

Opinions and views expressed by authors are their own and do not necessarily reflect the views of the publisher, MBL Communications, Inc., *CNS Spectrums*, LLC, or the editorial advisory board. The publisher is not guaranteeing or warranting or assuming any liability or responsibility for or with respect to and expressly disclaims any liability or responsibility for or with respect to this publication or the information contained in it.

Although every effort has been made to ensure that drug doses and other information are presented accurately in this publication, the ultimate responsibility rests with the prescribing physician. Neither the publisher nor the authors can be held responsible for errors or for any consequences arising from the use or misuse of information contained herein. The information contained in *CNS Spectrums* is intended for general educational and informational purposes; it is not intended as the sole basis upon which any action is to be recommended or taken.

Readers are strongly urged to consult any relevant primary literature. No claims or endorsements are made for any drug or compound currently under clinical investigation. The readers of this publication use and evaluate the information contained in this publication at their own risk.

Copyright © 2009 by MBL Communications, Inc. *CNS Spectrums* is a registered trademark of *CNS Spectrums*, LLC, New York, NY. Permission to reproduce articles in whole or part must be obtained in writing from the publisher. Printed in the USA. All rights reserved, including the right of reproduction, in whole or in part, in any form. Reproduction without permission is prohibited.

## EDITORS

### **EDITOR IN CHIEF**

Andrew A. Nierenberg, MD  
Harvard Medical School  
Boston, MA

### **FOUNDING EDITOR**

Eric Hollander, MD  
Institute of Clinical Neuroscience  
New York, NY

### **INTERNATIONAL EDITOR**

Joseph Zohar, MD  
Chaim Sheba Medical Center  
Tel-Hashomer, Israel

### **ASSOCIATE INTERNATIONAL EDITORS**

#### **EUROPE**

Donatella Marazziti, MD  
University of Pisa  
Pisa, Italy

#### **MID-ATLANTIC**

Dan J. Stein, MD, PhD  
University of Cape Town  
Cape Town, South Africa

#### **ASIA**

Shigeto Yamawaki, MD, PhD  
Hiroshima University School  
of Medicine  
Hiroshima, Japan

### **CONTRIBUTING WRITERS**

Maria Alice de Mathis, MA  
Rani A. Desai, PhD, MPH  
Debra R. Kahn, MD  
Michael Berk, MBBCh, MMed(Psych),  
FF(Psych)SA, FRANZCP, PhD

### **FIELD EDITOR**

Michael Trimble, MD, FRCP, FRPsych

### **COLUMNISTS**

Uriel Halbrich, MD  
Sarah H. Lisanby, MD  
Stefano Pallanti, MD, PhD  
Thomas E. Schlaepfer, MD  
Stephen M. Stahl, MD, PhD  
Dan J. Stein, MD, PhD

### **CME COURSE DIRECTOR**

James C.-Y. Chou, MD

### **SUPPLEMENT EDITOR**

Joseph Zohar, MD

## EDITORIAL ADVISORY BOARD

Lenard Adler, MD  
New York University Medical School  
New York, NY

Dennis S. Charney, MD  
Mount Sinai School of Medicine  
New York, NY

Jeffrey L. Cummings, MD  
University of California, Los Angeles  
Los Angeles, CA

John Geddes, MD, FRCPsych  
University of Oxford  
Oxford, United Kingdom

Mark S. George, MD  
Medical University of South Carolina  
Charleston, SC

Daphne Holt, MD  
Massachusetts General Hospital  
Charlestown, MA

Andres M. Kanner, MD  
Rush University  
Chicago, IL

Siegfried Kasper, MD  
University of Vienna  
Vienna, Austria

Yves Lecrubier, MD  
Hôpital de la Salpêtrière  
Paris, France

Sarah H. Lisanby, MD  
Columbia University  
New York, NY

Herbert Y. Meltzer, MD  
Vanderbilt University Medical Center  
Nashville, TN

Mario F. Mendez, MD  
University of California, Los Angeles  
Los Angeles, CA

Philip Mitchell, MB BS, MD, FRANZCP,  
FRCPsych  
University of New South Wales  
Sydney, Australia

Stuart A. Montgomery, MD  
St. Mary's Hospital Medical School  
London, United Kingdom

Humberto Nicolini, MD, PhD  
National Mexican Institute of Psychiatry  
Mexico City, Mexico

Stefano Pallanti, MD, PhD  
University of Florence  
Florence, Italy

Katharine Phillips, MD  
Brown Medical School  
Providence, RI

Diego A. Pizzagalli, PhD  
Harvard University  
Boston, MA

Mark H. Pollack, MD  
Massachusetts General Hospital  
Charlestown, MA

Mark Rapaport, MD  
University of California, Los Angeles  
Los Angeles, CA

Scott L. Rauch, MD  
Massachusetts General Hospital  
Charlestown, MA

Peter P. Roy-Byrne, MD  
University of Washington School of Medicine  
Seattle, WA

Gerard Sanacora, MD  
Yale University  
New Haven, CT

Alan F. Schatzberg, MD  
Stanford University School of Medicine  
Stanford, CA

Thomas E. Schlaepfer, MD  
University of Bonn  
Bonn, Germany

Jordan W. Smoller, MD, ScD  
Massachusetts General Hospital  
Charlestown, MA

Stephen M. Stahl, MD, PhD  
University of California, San Diego  
La Jolla, CA

Stephen Strakowski, MD  
University of Cincinnati  
Cincinnati, OH

Scott Stroup, MD, MPH  
University of North Carolina, Chapel Hill  
Chapel Hill, NC

Norman Sussman, MD  
New York University Medical School  
New York, NY

Pierre N. Tariot, MD  
University of Arizona  
Phoenix, AZ

Michael E. Thase, MD  
University of Pennsylvania School of Medicine  
Philadelphia, PA

Michael Trimble, MD, FRCP, FRPsych  
National Hospital for Neurology  
and Neurosurgery  
London, United Kingdom

Madhukar H. Trivedi, MD  
University of Texas Southwestern Medical Center  
Dallas, TX

Karen Dineen Wagner, MD, PhD  
The University of Texas Medical Branch  
Galveston, TX

Herman G.M. Westenberg, MD  
University Hospital Utrecht  
Utrecht, The Netherlands

Carlos A. Zarate, Jr., MD  
National Institute of Mental Health  
Bethesda, MD

## PUBLICATION STAFF

### **CEO & PUBLISHER**

Darren L. Brodeur

### **VP, MANAGING EDITOR**

Christopher Naccari

### **VP, HUMAN RESOURCES**

Kimberly A. Brodeur

### **SENIOR PROJECTS EDITOR**

Deborah Hughes Levy

### **SENIOR EDITOR-PRIMARY PSYCHIATRY**

Dena Croog

### **EDITOR-CNS SPECTRUMS**

Virginia Jackson

### **ASSOCIATE EDITOR**

Lonnie Stoltzfoos

### **ASSISTANT EDITOR**

Carlos Perkins, Jr.

### **SENIOR ACQUISITIONS EDITOR**

Lisa Arrington

### **WEBMASTER**

Shamar Rose

### **EDITORIAL INTERN**

Amanda Cuomo

### **CME DEVELOPMENT MANAGERS**

Annette Schwind  
Shelley Wong

### **ASSISTANT-CME ADMINISTRATION**

Sonny Santana

### **ART DIRECTOR**

Derek Oscarson

### **GRAPHIC DESIGNER**

Michael J. Vodilko

### **CHIEF FINANCIAL OFFICER**

John Spano

### **ACCOUNTING INTERN**

Stephanie Spano

### **SALES & EVENT COORDINATOR**

Kimberly Schneider

### **INFORMATION TECHNOLOGY**

Clint Bagwell Consulting

### **CORPORATION COUNSEL**

Lawrence Ross, Esq.  
Bressler, Amery, and Ross

**MBL**  
communications

Publishers of

**PRIMARY PSYCHIATRY**  
The Largest Peer Reviewed Psychiatric Journal in the Nation

**CNS SPECTRUMS**  
The International Journal of Neuropsychiatric Medicine

**Psychiatry Weekly**  
The Leading News Service from Primary Psychiatry and Psychiatry's Weekly

**ADS**  
The Annual Research Review  
ALZHEIMER'S DISEASE SUMMIT













The Master Psychopharmacology Program is intended as recognition for study in psychopharmacology that goes far beyond keeping CME up to date. Completion of the Master Psychopharmacology Program shows serious interest and investment in the field by those who attain Master Psychopharmacologist recognition. The program consists of 10 self-assessment exams (SAEs), each covering an individual topic, 24 online Fellowship activities, and one final exam. Candidates have 12 months to fulfill these requirements, and achieve the Master Psychopharmacologist designation.

## NEI Membership

Prerequisite





## Self-Assessment Exams (Online)

10 exams

- |  |   |
|--|---|
|  Basic Neuroscience           |  Substance Use Disorders             |
|  Psychosis and Schizophrenia |  Dementia and Cognitive Function    |
|  Unipolar Depression        |  Fibromyalgia, Functional Somatic  |
|  Bipolar Disorders          | Syndromes, and Chronic Pain   |
|  Anxiety Disorders          |  Disorders of Sleep/Wake and Their |
|  ADHD                       | Comorbidities With Psychiatric Illness  |

## Fellowship Activities (Online)

24 activities

- |  |   |
|--|---|
|  6 Articles             |  6 Case-Based Drills             |
|  6 Audiovisual Snippets |  6 Animated Mechanisms of Action |

A different Fellowship activity is released once a week.

## Final Exam (Online)

\$249 / attempt



Enroll today at [www.neiglobal.com/mpp](http://www.neiglobal.com/mpp)

**EDITORIAL****344 Distress: To Treat or Not to Treat?**Andrew A. Nierenberg, MD, *Harvard Medical School***CLINICAL UPDATES IN NEUROPSYCHIATRY**

- 351**
- *FDA Approves lacosamide for the Treatment of Epileptic Seizures*
  - *Alzheimer's Disease May Be Predictable by Measuring Brain's Memory Center*

**PEARLS IN CLINICAL NEUROSCIENCE****352 Borderline Personality Disorder: Toward Integration**Dan J. Steinl, MD, PhD, *University of Cape Town***LETTER TO THE EDITOR****346 Varenicline-induced Mixed Mood and Psychotic Episode in a Patient with Schizoaffective Disorder****ORIGINAL RESEARCH****362 Early Onset Obsessive-Compulsive Disorder With and Without Tics**

Maria Alice de Mathis, MS, Juliana B. Diniz, MD, and Roseli G. Shavitt, MD, PhD, *University of São Paulo Medical School*; Albina R. Torres, MD, PhD, *Botucatu Medical School*; Ygor A. Ferrão, MD, PhD, *Porto Alegre Institute*; Victor Fossaluza, BA, and Carlos Pereira, PhD, *University of São Paulo*; Eurípedes C. Miguel, MD, PhD, *São Paulo Medical School*; and Maria Conceição do Rosario, MD, PhD *Federal University of São Paulo*.

**372 Gender Differences in the Association Between Body Mass Index and Psychopathology**

Rani A. Desai, PhD, *Yale University*, MPH, Melinda Manley, MA, MPhil, Mayur M. Desai, PhD, MPH, and Marc N. Potenza, PhD, MD, *Yale University*

**CASE REPORTS****385 A Case of Alcohol Withdrawal Requiring 1,600 mg of Lorazepam in 24 Hours**

Debra R. Kahn, MD, *University of California, Davis*; Amy V. Barnhorst, MD, *University of California, Davis*; and James A. Bourgeois, OD, MD, *University of California, Davis*

**357 Nail-Biting Stuff? The Effect of N-acetyl Cysteine on Nail-Biting**

Michael Berk, MBCh, MMed(Psych), FF(Psych)SA, FRANZCP, PhD, *University of Melbourne*; Sue Jeavons, BA (Hons), MPhil, PhD, *Mental Health Research Institute*; Olivia M. Dean, BSc, PhD, *Mental Health Research Institute*; Seetal Dodd, BSc, DipEd, MSc, PhD, *University of Melbourne*; Kirsteen Moss, Bsc-Psych (Hons), *University of Sydney*; Clarissa S. Gama, PhD, *Hospital de Clínicas de Porto Alegre*; and Gin S Malhi, MBChB, BSc (Hons), FRCPsych, FRANZCP, *University of Sydney*

**CME EXPERT PANEL SUPPLEMENT****Differential Diagnosis of Adult Attention-Deficit/Hyperactivity Disorder: Treatment Options and Comorbidity Considerations**

David Goodman, MD, Oscar Bukstein, MD, MPH, and Roger McIntyre, MD, FRCPC



CME 2

PSYCHIATRISTS,  
YOUR PROFESSIONAL LIABILITY INSURER  
MAY NO LONGER BE SAFE OR SOUND.

MAKE SURE YOUR PROFESSIONAL  
LIABILITY INSURANCE  
IS PROVIDED BY A COMPANY  
WITH AN "EXCELLENT" RATING.  
AND DON'T SETTLE FOR  
ANYTHING LESS.

YOUR FUTURE COULD  
DEPEND ON IT!

### Darwin National Assurance Company




Darwin is rated "Excellent" by  
A.M. Best Co. and anticipates a  
further upgrade in its rating  
very soon not a downgrade.

### Discounts

- 50% for Part-time
- 10% Claims free
- 50% as a New Graduate
- 5% Risk Management and a discounted course available on our website

(Please call 1-800-421-6694 for complete details  
on these discounts.)



95 Broadway, Amityville, NY 11701

Endorsed By:

AMERICAN ACADEMY OF  
CHILD & ADOLESCENT  
PSYCHIATRY

1-800-421-6694

www.americanprofessional.com